S1



S2



S3



S4



S5



S6



supplemental figures set 1

S7



S10



S8



S11



S9



supplemental figures set 2

Supplementary Figure Legend

Supplementary Figure S1 - Experiment was performed as indicated in Figure 1c, except that normal melanocytes were used for the analysis, $P< 0.01$.

Supplementary Figure S2 - Analysis of CSL effect on viability of normal melanocytes was performed as detailed in Figure 1c, $P< 0.05$.

Supplementary Figure S3 - SW1 cells were transfected with the TRE-luciferase plasmid and 24h later cells were treated with the indicated doses of AIGA for 8h before proteins were prepared and level of luciferase activity was measured. $ATF2^{50–100}$ peptide was used as a positive control. Data shown represent results from 3 experiments, $P< 0.0035$.

Supplementary Figure S4 - The effect of AIGA on ATF2 transcriptional activities, measured by the Jun2-luciferase plasmid transfected into SW1 cells was assessed as detailed in panel a, $P< 0.0045$.

Supplementary Figure S5 - Transcriptional activation of NFκ-B was assessed using the 2-NFκ-B-luciferase plasmid following treatment of cells with AIGA, using the experimental protocol outlined in panel a. Results shown represent 2 experiments, $P< 0.01$.

Supplementary Figure S6 - SW1 cells were treated with indicated doses of AIGA and CSL for 1h. UVC was used as a control. Total protein extracts were used to determine the phosphorylation of ERK1/2, total levels of ERK1/2, phospho AKT and total AKT levels.

Supplementary Figure S7 - SW1 cells were pretreated (for 30 min) with the JNK inhibitor SP600125 (10μM) followed by addition of AIGA for 20h. ATP levels were used to measure the cell viability using the ATP-lite kit. Calculation for altered viability was performed as detailed in legend to Fig 1c. Shown are representative results from 2 experiments. $P< 0.01$.

Supplementary Figure S8 - Western blot analysis for JNK phosphorylation on residues 183/185 was performed on protein extracts that were prepared from cells treated with AIGA, as indicated in panel S7. Lower panel depicts total level of JNK.

Supplementary Figure S9 - SW1 cells were treated with AIGA at the indicated concentrations, and the degree of apoptosis, measured by FACS analysis, was determined 48 h later. Data shown represents three different experiments.

Supplementary Figures S10, S11 - Human melanoma WM115 (S10) or MeWO (S11) cells were treated with the indicated doses of AIGA for 20h. ATP levels were used to

measure the cell viability using the ATP-lite kit. Calculation was performed as detailed in legend to Fig 1c. Shown are representative results from 3 experiments.